SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
GLP-1
GLP-1s Could Protect Against Neurodegeneration, Study Finds
A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and stroke, hinting at potential neuroprotective effects of GLP-1 therapies.
July 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Sarepta’s Wild Week, CDER’s New Leader, FDA Rejections, Manufacturing Billions
Sarepta Therapeutics faces serious FDA action after news broke of a third patient death, the FDA gets a new top drug regulator in George Tidmarsh, a handful of new drugs get turned away from the market and pharma companies continue to commit billions to reshoring manufacturing.
July 23, 2025
 · 
1 min read
 · 
Jef Akst
continuous single line drawing of confident woman in business attire, arms crossed, line art vector illustration
C-suite
Zhen Li: A Reluctant Engineer Shaping the World of siRNA
ADARx Pharmaceuticals CEO Zhen Li found her way to biopharma through Merck, where she was inspired by the application of powerful science to human medicine.
July 23, 2025
 · 
4 min read
 · 
Annalee Armstrong
Female Public Speaker On Lectern In Front Of Audience.
Editorial
Advice From Women in Biopharma: ‘Resilience Is a Critical Feature’
When talking to some of the most impressive women in biopharma, the conversation inevitably turned to what these women wanted other entrepreneurs to know. Here’s the best of the best of that advice.
July 23, 2025
 · 
3 min read
 · 
Annalee Armstrong
A pop art image of two hands polishing a vase
Editorial
Lack of Transparency Tarnishes Sarepta’s Sheen as Patient Deaths Trigger FDA Battle
Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the regulator considers more drastic action.
July 22, 2025
 · 
6 min read
 · 
Jef Akst
A finger presses down on a businessman. Art collage.
Immuno-oncology
Replimune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment
BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the agency’s decision to issue a complete response letter for Replimune’s viral treatment RP1 for advanced melanomas. Shares of the company tumbled 75% on Tuesday.
July 22, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Close-Up Of Syringe With Bottles Against Blue Background
Mergers & acquisitions
Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition
The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, follows the pharma’s potential $1.4 billion COVID vaccine licensing deal with Novavax last year, plus a number of other big-ticket commitments outside of the vaccine space.
July 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: AstraZeneca's manufacturing facility in Sweden
Manufacturing
With Potential Tariffs Weeks Away, AstraZeneca Makes $50B U.S. Manufacturing Push
The money will focus on a manufacturing plant in Virginia that will make the company’s weight management and metabolic drugs like the hypertension drug baxdrostat and oral GLP-1 therapies.
July 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Big fish with a dollar badge wants to eat small fish
Mergers & acquisitions
Concentra Buys Beleaguered iTeos at Slight Discount
In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage performance of its anti-TIGIT antibody belrestotug.
July 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS